Unknown

Dataset Information

0

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.


ABSTRACT: PURPOSE:The novel dual-action humanized IgG1 antibody MEHD7945A targeting HER3 and EGFR inhibits ligand-dependent HER dimer signaling. This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of MEHD7945A. EXPERIMENTAL DESIGN:Patients with locally advanced or metastatic epithelial tumors received escalating doses of MEHD7945A (1-30 mg/kg) every 2 weeks (q2w) until disease progression or intolerable toxicity. An expansion cohort was enrolled at the recommended phase II dose (14 mg/kg, q2w). Plasma samples, tumor biopsies, FDG-PET were obtained for assessment of pharmacokinetics, and pharmacodynamic modulation downstream of EGFR and HER3. RESULTS:No dose-limiting toxicities or MEHD7945A-related grade ? 4 adverse events (AE) were reported in dose-escalation (n = 30) or expansion (n = 36) cohorts. Related grade 3 AEs were limited to diarrhea and nausea in the same patient (30 mg/kg). Related AEs in ?20% of patients ?24 hours after the first infusion included grade 1/2 headache, fever, and chills, which were managed with premedication and/or symptomatic treatment. Pharmacodynamic data indicated target inhibition in 25% of evaluable patients. Best response by RECIST included 2 confirmed partial responses in squamous cell carcinomas of head and neck (SCCHN) patients with high tumor tissue levels of the HER3 ligand heregulin; 14 patients had stable disease ?8 weeks, including SCCHN (n = 3), colorectal cancer (n = 6), and non-small cell lung cancer (n = 3). CONCLUSIONS:MEHD7945A was well-tolerated as single agent with evidence of tumor pharmacodynamic modulation and antitumor activity in SCCHN. Phase II studies were initiated with flat (nonweight-based) dosing at 1,100 mg q2w in SCCHN and colorectal cancer.

SUBMITTER: Juric D 

PROVIDER: S-EPMC5705193 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

Juric Dejan D   Dienstmann Rodrigo R   Cervantes Andres A   Hidalgo Manuel M   Messersmith Wells W   Blumenschein George R GR   Tabernero Josep J   Roda Desamparados D   Calles Antonio A   Jimeno Antonio A   Wang Xiaodong X   Bohórquez Sandra Sanabria SS   Leddy Cecilia C   Littman Catherine C   Kapp Amy V AV   Shames David S DS   Penuel Elicia E   Amler Lukas C LC   Pirzkall Andrea A   Baselga José J  

Clinical cancer research : an official journal of the American Association for Cancer Research 20150601 11


<h4>Purpose</h4>The novel dual-action humanized IgG1 antibody MEHD7945A targeting HER3 and EGFR inhibits ligand-dependent HER dimer signaling. This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of MEHD7945A.<h4>Experimental design</h4>Patients with locally advanced or metastatic epithelial tumors received escalating doses of MEHD7945A (1-30 mg/kg) every 2 weeks (q2w) until disease progression or intolerable toxicity. An expansion cohort was enroll  ...[more]

Similar Datasets

| S-EPMC3139984 | biostudies-literature
| S-EPMC7254871 | biostudies-literature
| S-EPMC6136933 | biostudies-literature
| S-EPMC7417410 | biostudies-literature
| S-EPMC4254850 | biostudies-literature
| S-EPMC4293119 | biostudies-literature
| S-EPMC8026416 | biostudies-literature
| S-EPMC7935407 | biostudies-literature
| S-EPMC7226106 | biostudies-literature
| S-EPMC8645912 | biostudies-literature